Lactic Acid Bacteria Compositions for HIF-1alpha Oxygenation Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for hypoxia-inducing conditions, such as chronic fatigue, neurodegenerative diseases, and respiratory failure, do not effectively modulate cellular levels of hypoxia-inducible factor HIF-1α to enhance oxygenation and reduce oxygen consumption.
Innovation Solution
Oral administration of specific strains of lactic acid bacteria, including Lactobacillus acidophilus, Streptococcus thermophilus, and Bifidobacterium animalis subsp. lactis, which increase HIF-1α levels and reduce cellular oxygen consumption, formulated into compositions for oral delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional lactic acid bacteria strains are used, then probiotic functions are provided, but they cannot modulate body oxygenation or increase HIF-1alpha levels
Solution Approach 1:
The patent identifies specific genetic parameters (presence of hif-1alpha, fur, and slyA genes; absence of hyl gene) that differentiate conventional probiotics from the novel strains. By selecting bacteria with these specific genetic parameters, the invention achieves both probiotic functionality and the ability to modulate body oxygenation through HIF-1alpha induction.
2Quantity of substance
If existing probiotic strains are administered, then general health benefits are achieved, but specific oxygenation modulation and HIF-1alpha increase effects are not obtained
Solution Approach 1:
The patent applies local quality by specifying particular genetic characteristics that must be present in the bacterial strain. The selection criteria focus on specific genes (hif-1alpha, fur, slyA presence and hyl absence) rather than general probiotic properties, creating a localized genetic profile that enables precise HIF-1alpha induction and oxygenation modulation effects.
3Adaptability or versatility
If non-specific probiotic strains are used, then broad probiotic coverage is provided, but targeted HIF-1alpha induction and oxygenation effects are not achieved
Solution Approach 1:
The invention changes the selection parameters from general probiotic characteristics to specific genetic markers. By requiring the presence of hif-1alpha, fur, and slyA genes and absence of the hyl gene, the patent creates a refined parameter set that ensures reliable HIF-1alpha induction while maintaining probiotic functionality.
Data Source
Figure 1a~2d
Figure 3~4c
Figure 5a~5f
AI summary
The invention relates to particular species, strains, and compositions of lactic acid bacteria capable of increasing cellular levels of the hypoxia-inducible factor HIF-1α for the maintenance or enhancement of normoxia in hypoxia-inducing conditions such as, for example, physical exertion, lethargy, chronic fatigue, oxygen deficiency, travel beyond the limits of the earth's atmosphere, oxidative stress of eyeballs and scuba diving, or for the treatment of hypoxia in hypoxia-inducing conditions such as neurodegenerative diseases, pulmonary implications associated with respiratory failure, neonatal hypoxia-ischemia, myocardial ischemia, metabolic disorders, chronic cardiac and renal diseases, reproductive disorders such as pre- eclampsia and endometriosis, exacerbation of postural and kinetic tremors, and cerebral hypoxia.